1-8 of 8
James A. Zwiebel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, Funda Meric-Bernstam, Melissa S. Dillmon, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Andrew J. Aguirre, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 2996–3004.
https://doi.org/10.1158/1078-0432.CCR-21-0066
Published: 01 June 2021
View article titled, Differential Outcomes in Codon 12/13 and Codon 61 <em>NRAS</em>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <em>NRAS</em>-Mutated Tumors
Open the PDF for Differential Outcomes in Codon 12/13 and Codon 61 <em>NRAS</em>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <em>NRAS</em>-Mutated Tumors in another window
Includes: Supplementary data
Journal Articles

Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual

Holly A. Massett, Grace Mishkin, Larry Rubinstein, S. Percy Ivy, Andrea Denicoff, Elizabeth Godwin, Kate DiPiazza, Jennifer Bolognese, James A. Zwiebel, Jeffrey S. Abrams
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5408–5416.
https://doi.org/10.1158/1078-0432.CCR-16-0338
Published: 14 November 2016
View article titled, Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Open the PDF for Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual in another window
Journal Articles

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors

Marwan G. Fakih, Gerald Fetterly, Merrill J. Egorin, Josephia R. Muindi, Igor Espinoza-Delgado, James A. Zwiebel, Alan Litwin, Julianne L. Holleran, Kangsheng Wang, Robert B. Diasio
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3786–3794.
https://doi.org/10.1158/1078-0432.CCR-10-0547
Published: 14 July 2010
View article titled, A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
Open the PDF for A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors in another window
Journal Articles

A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors

Jianqing Lin, Jill Gilbert, Michelle A. Rudek, James A. Zwiebel, Steve Gore, Anchalee Jiemjit, Ming Zhao, Sharyn D. Baker, Richard F. Ambinder, James G. Herman, Ross C. Donehower, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6241–6249.
https://doi.org/10.1158/1078-0432.CCR-09-0567
Published: 30 September 2009
View article titled, A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
Open the PDF for A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

Marwan G. Fakih, Lakshmi Pendyala, Gerald Fetterly, Karoli Toth, James A. Zwiebel, Igor Espinoza-Delgado, Alan Litwin, Youcef M. Rustum, Mary Ellen Ross, Julianne L. Holleran, Merrill J. Egorin
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3189–3195.
https://doi.org/10.1158/1078-0432.CCR-08-2999
Published: 30 April 2009
View article titled, A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Open the PDF for A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer in another window
Journal Articles

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Rebecca B. Klisovic, William Blum, Xiaohui Wei, Shujun Liu, Zhongfa Liu, Zhiliang Xie, Tamara Vukosavljevic, Cheryl Kefauver, LeNguyen Huynh, Jiuxia Pang, James A. Zwiebel, Steven Devine, John C. Byrd, Michael R. Grever, Kenneth Chan, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3889–3895.
https://doi.org/10.1158/1078-0432.CCR-08-0109
Published: 16 June 2008
View article titled, Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Open the PDF for Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia in another window
Journal Articles

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

Suresh S. Ramalingam, Robert A. Parise, Ramesh K. Ramananthan, Theodore F. Lagattuta, Lori A. Musguire, Ronald G. Stoller, Douglas M. Potter, Athanassios E. Argiris, James A. Zwiebel, Merrill J. Egorin, Chandra P. Belani
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3605–3610.
https://doi.org/10.1158/1078-0432.CCR-07-0162
Published: 15 June 2007
View article titled, Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies in another window
Journal Articles

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7851–7860.
https://doi.org/10.1158/1078-0432.CCR-05-0262
Published: 08 November 2005
View article titled, Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Open the PDF for Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion in another window